title: [Antibiotic prophylaxis in oncologic surgery].
abstract: Perioperative antibiotic administration can decrease surgical morbidity, shorten hospitalization, while lowering the overall costs attributable to infections. Its use in surgery is widespread and often inappropriate. In this study, the authors evaluate the guidelines for selection and use of prophylactic antibiotics in surgical cancer patients at the Hospital of Cancer in Rio de Janeiro, Brazil. During 36 non-consecutive months, 1681 cancer patients submitted to surgical procedures were prospectively followed-up by members of the Hospital Infection Control Committee. The overall surgical site infection (SSI) and mortality rates were 17.7% and 4.8% respectively. Prophylactic antibiotics were used in 1262 elective surgeries (75.1%), and their use was not considered to be in accordance with the recommended protocol in 37.6% of the cases. The inadequate antimicrobial prophylaxis resulted in higher incidence of SSI than did prophylaxis in according to the protocol (21.7% vs. 16.4, Relative Risk 1.32; 95% Confidence Internal 1.05-1.67; p0.01). This study calls the attention for the need of a more strict and determined educational program in order to provide mechanisms for an adequate administration of prophylactic antibiotics to patients submitted to high-risk surgeries.
authors.affiliation: Comissão de Controle de Infecção Hospitalar do Hospital do Cãncer do Instituo Nacional do Câncer do Rio de Janeiro.
authors.forename: E
authors.initials: E
authors.lastname: Velasco
authors.forename: L C
authors.initials: LC
authors.lastname: Thuler
authors.forename: C A
authors.initials: CA
authors.lastname: Martins
authors.forename: L M
authors.initials: LM
authors.lastname: Dias
authors.forename: V M
authors.initials: VM
authors.lastname: Gonçalves
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019072:Antibiotic Prophylaxis / Q000191:economics / Q000379:methods / Q000592:standards; D002437:Cefazolin / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D016001:Confidence Intervals; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use*; D008875:Middle Aged; D009369:Neoplasms / Q000601:surgery*; D010406:Penicillins / Q000627:therapeutic use*; D011446:Prospective Studies; D012307:Risk Factors; D013530:Surgical Wound Infection / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D010406:Penicillins; D008795:Metronidazole; D002437:Cefazolin